Zobrazeno 1 - 10
of 59
pro vyhledávání: '"J Connor Wells"'
Autor:
J. Connor Wells, Adam Fundytus, Shubham Sharma, Wilma M. Hopman, Joseph C. Del Paggio, Bishal Gyawali, Deborah Mukherji, Nazik Hammad, C. S. Pramesh, Ajay Aggarwal, Richard Sullivan, Christopher M. Booth
Publikováno v:
Current Oncology, Vol 29, Iss 4, Pp 2530-2538 (2022)
Background: In this study, we compared and contrasted design characteristics, results, and publications of randomized controlled trials (RCTs) in gastrointestinal (GI), lung, and breast cancer. Methods: A PUBMED search identified phase III RCTs of an
Externí odkaz:
https://doaj.org/article/3692da3d8bdf477ab3d3a73898ca874c
Autor:
Shubham Sharma, J. Connor Wells, Wilma M. Hopman, Joseph C. Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E. Hay, Christopher M. Booth
Publikováno v:
Current Oncology, Vol 28, Iss 2, Pp 1518-1527 (2021)
Canada has a long tradition of leading practice-changing clinical trials in oncology. Here, we describe methodology, results, and interpretation of oncology RCTs with Canadian involvement compared to RCTs from other high-income countries (HICs). A li
Externí odkaz:
https://doaj.org/article/47e3eda2b6014516883c1a3349a9f772
Autor:
Chun Loo Gan, Shaan Dudani, J. Connor Wells, Frede Donskov, Sumanta K. Pal, Nazli Dizman, Nityam Rathi, Benoit Beuselinck, Flora Yan, Aly‐Khan A. Lalani, Aaron Hansen, Bernadett Szabados, Guillermo deVelasco, Ben Tran, Jae Lyun Lee, Ulka N. Vaishampayan, Georg A. Bjarnason, Mathushan Subasri, Toni K. Choueiri, Daniel Y. C. Heng
Publikováno v:
Cancer Medicine, Vol 10, Iss 4, Pp 1212-1221 (2021)
Abstract Background Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real‐world effectiveness and dosing patterns of cabozantinib are not well characterized. Methods Patients with
Externí odkaz:
https://doaj.org/article/7d15b141c0ef4643936c243f3bc0a02a
Autor:
Dominick Bossé, Wanling Xie, Xun Lin, Ronit Simantov, Aly-Khan A. Lalani, Jeffrey Graham, J. Connor Wells, Frede Donskov, Brian Rini, Benoit Beuselinck, Ajjai Alva, Aaron Hansen, Lori Wood, Denis Soulières, Christian Kollmannsberger, Francois Patenaude, Daniel Y.C. Heng, Toni K. Choueiri, Rana R. McKay
Publikováno v:
JCO Global Oncology, Vol , Iss 6, Pp 293-306 (2020)
PURPOSETo investigate whether black race is an independent predictor of overall survival (OS) in metastatic renal cell carcinoma (mRCC).METHODSWe performed a retrospective 2-cohort (International Metastatic Renal Cell Carcinoma Database Consortium [I
Externí odkaz:
https://doaj.org/article/7f8755e52c91411ab1c49335f24de728
Autor:
Ziad Bakouny, Talal El Zarif, Shaan Dudani, J. Connor Wells, Chun Loo Gan, Frede Donskov, Julia Shapiro, Ian D. Davis, Francis Parnis, Praful Ravi, John A. Steinharter, Neeraj Agarwal, Ajjai Alva, Lori Wood, Anil Kapoor, Jose M. Ruiz Morales, Christian Kollmannsberger, Benoit Beuselinck, Wanling Xie, Daniel Y.C. Heng, Toni K. Choueiri
Publikováno v:
European Urology. 83:145-151
The role of upfront cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) in the era of immune checkpoint inhibitors is unclear.To evaluate the relationship between upfront CN and clinical outcomes in the setting of mRCC treated w
Autor:
Toni K. Choueiri, Darren Feldman, Robert J. Motzer, Sabina Signoretti, Lauren C. Harshman, James J. Hsieh, Jae Lyun Lee, Sumanta K. Pal, JoAnn Hsu, Fabio A. Schutz, Andre P. Fay, Daniel Y. Heng, J. Connor Wells, Guillermo De Velasco, Daniel Castellano, Eliezer Van Allen, David A. Braun, Xiao X. Wei, Dylan J. Martini, Aly-Khan A. Lalani, Raphael Brandao, Abdallah Flaifel, Stephanie A.M. Wankowicz, Wanling Xie, Dominick Bossé, Rana R. McKay
Programmed death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors have shown activity in metastatic clear cell renal cell carcinoma (ccRCC). Data on the activity of these agents in patients with non–clear cell RCC (nccRCC) or patients with sarcomatoid/r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc7a3b136f17fc5d33e77f0d7330319b
https://doi.org/10.1158/2326-6066.c.6549214.v1
https://doi.org/10.1158/2326-6066.c.6549214.v1
Autor:
Toni K. Choueiri, Darren Feldman, Robert J. Motzer, Sabina Signoretti, Lauren C. Harshman, James J. Hsieh, Jae Lyun Lee, Sumanta K. Pal, JoAnn Hsu, Fabio A. Schutz, Andre P. Fay, Daniel Y. Heng, J. Connor Wells, Guillermo De Velasco, Daniel Castellano, Eliezer Van Allen, David A. Braun, Xiao X. Wei, Dylan J. Martini, Aly-Khan A. Lalani, Raphael Brandao, Abdallah Flaifel, Stephanie A.M. Wankowicz, Wanling Xie, Dominick Bossé, Rana R. McKay
Includes: Table 1S. Baseline patient and disease characteristics. Table 2S. Tumor mutation burden status. Table 3S. PDL1 expression data. Figure 1S. Overall survival for the total cohort.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::050a1b150ce3998dd89220d1a3afb6e9
https://doi.org/10.1158/2326-6066.22539886.v1
https://doi.org/10.1158/2326-6066.22539886.v1
Autor:
Donna L. Senger, Stephen M. Robbins, David R. Kaplan, J. Gregory Cairncross, Samuel Weiss, Artee Luchman, Jacob C. Easaw, Jeffrey L. Wrana, Alessandro Datti, David Uehling, Ahmed Aman, Xiuling Wang, Ngoc-Ha Dang, Xiaoguang Hao, Jennifer C. King, Natalie Grinshtein, J. Connor Wells, Xueqing Lun
Purpose: Glioblastoma is one of the most lethal cancers in humans, and with existing therapy, survival remains at 14.6 months. Current barriers to successful treatment include their infiltrative behavior, extensive tumor heterogeneity, and the presen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::352984f9333967436036ef5f69a99520
https://doi.org/10.1158/1078-0432.c.6523565.v1
https://doi.org/10.1158/1078-0432.c.6523565.v1
Autor:
Donna L. Senger, Stephen M. Robbins, David R. Kaplan, J. Gregory Cairncross, Samuel Weiss, Artee Luchman, Jacob C. Easaw, Jeffrey L. Wrana, Alessandro Datti, David Uehling, Ahmed Aman, Xiuling Wang, Ngoc-Ha Dang, Xiaoguang Hao, Jennifer C. King, Natalie Grinshtein, J. Connor Wells, Xueqing Lun
Figure S1: Preclinical assessment of clioquinol. Figure S2: Preclinical assessment of montelukast. Figure S3: Secondary validation of compounds identified via HTS. Figure S4: Sensitivity of BTICs to TMZ. Figure S5: Copper is required for Disulfiram-m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47c1d45a5657bc581427aa74a1e03623
https://doi.org/10.1158/1078-0432.22457381.v1
https://doi.org/10.1158/1078-0432.22457381.v1
Autor:
Vishal Navani, J Connor Wells, Devon J Boyne, Winson Y Cheung, Darren M Brenner, Bradley A McGregor, Chris Labaki, Andrew L Schmidt, Rana R McKay, Luis Meza, Sumanta K Pal, Frede Donskov, Benoit Beuselinck, Maxwell Otiato, Lisa Ludwig, Thomas Powles, Bernadett E Szabados, Toni K Choueiri, Daniel Y C Heng
BACKGROUND: There are limited data evaluating the activity of cabozantinib (CABO) as second line (2L) therapy post standard of care ipilimumab-nivolumab (IPI-NIVO) or immuno-oncology(IO)/vascular endothelial growth factor inhibitor (VEGFi) combinatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a9fd530a1f2f3ecd64cfa5d480f36f4
https://lirias.kuleuven.be/handle/20.500.12942/717579
https://lirias.kuleuven.be/handle/20.500.12942/717579